Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates

• DOI: 10.1111/ijcp.12868
• Publication Date: 2016-09-07T03:44:11Z
• Authors: Mathew John; Sonia Cerdas; Rafael Violante; Chaicharn Deeroch...; Mohamed Hassanein; April Slee; William Canovatchel; Gill Hamilton
• Keywords: Canagliflozin; Glimepiride; Post-hoc analysis

Patients with type 2 diabetes mellitus (T2DM) have increased risk of adverse events (AEs; e.g. dehydration, hypoglycaemia) in hot weather. This analysis assessed the efficacy and safety canagliflozin, a sodium glucose co-transporter (SGLT2) inhibitor, patients T2DM who live climates.This post hoc evaluated using pooled data from four 26-week, placebo-controlled studies (N=2,313) 104-week, active-controlled study (add-on to metformin vs glimepiride; N=1,450). Changes HbA1c, fasting plasma (FPG), body weight blood pressure (BP) were subsets living climates (pooled, studies, n=611; study, n=307) those other (i.e. climate subset; pooled, n=1,702; n=1,143). Safety was based on AE reports.Canagliflozin 100 300 mg lowered FPG, BP placebo over 26 weeks glimepiride 104 subsets. Canagliflozin generally well tolerated subsets, higher incidence AEs related mechanism SGLT2 inhibition genital mycotic infections). Volume depletion-related low across groups.Canagliflozin improved glycaemic control, BP, compared or weeks.ClinicalTrials.gov NCT01081834, NCT01106677, NCT01106625, NCT01106690, NCT00968812.